Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.56 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.54 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6643834 | 0.87 | PTGS2 (0.53) | LMNAPTGS2SLC6A9PTGDR2 | |
| SCHEMBL1259335 | 0.87 | PTGDR2 (0.57) | LMNAPTGS2SLC6A9PTGDR2 | |
| SCHEMBL8259316 | 0.86 | LMNA (0.54) | LMNAPTGS2SLC6A9HSD17B10 | |
| SCHEMBL1812902 | 0.86 | PTGS2 (0.58) | LMNAPTGS2SLC6A9 | |
| SCHEMBL3875280 | 0.86 | LMNA (0.62) | LMNAPTGS2PTGDR2HSD17B10 | |
| SCHEMBL3873005 | 0.86 | LMNA (0.54) | LMNAPTGS2SLC6A9HSD17B10 | |
| SCHEMBL4940447 | 0.85 | PTGS2 (0.59) | LMNAPTGS2 | |
| SCHEMBL3884199 | 0.85 | SLC6A9 (0.53) | LMNAPTGS2SLC6A9 | |
| SCHEMBL3874637 | 0.84 | PTGS2 (0.65) | LMNAPTGS2SLC6A9PTGDR2 | |
| SCHEMBL4942150 | 0.83 | SMN1; SMN2 (0.70) | LMNAPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794593-B1 | SPIRO AMINIC COMPOUNDS AS OREXIN ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2017-02-01 | — | — | EP | disclosed |
| EP-2794593-B1 | SPIRO AMINIC COMPOUNDS AS OREXIN ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2017-02-01 | — | — | EP | disclosed |
| US-9062033-B2 | Chemical compounds | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-06-23 | — | — | US | disclosed |
| US-9062033-B2 | Chemical compounds | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-06-23 | — | — | US | disclosed |
| US-9062033-B2 | Chemical compounds | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-06-23 | — | — | US | disclosed |
| US-20140357653-A1 | CHEMICAL COMPOUNDS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-12-04 | — | — | US | disclosed |
| US-20140357653-A1 | CHEMICAL COMPOUNDS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-12-04 | — | — | US | disclosed |
| US-20140357653-A1 | CHEMICAL COMPOUNDS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-12-04 | — | — | US | disclosed |
| EP-2794593-A1 | CHEMICAL COMPOUNDS | Rottapharm Biotech S.r.l. (IT) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013092893-A1 | CHEMICAL COMPOUNDS | ROTTAPHARM SPA (IT) | 2013-06-27 | — | — | WO | disclosed |
| WO-2006094842-A1 | ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006082001-A1 | HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006082001-A1 | HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-10 | — | — | WO | disclosed |
| US-20060178381-A1 | Heterocyclic-substituted phenyl methanones | HOFFMANN-LA ROCHE INC. | 2006-08-10 | — | — | US | disclosed |
| WO-2006079467-A1 | PHENYL METHANONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER 1 INHIBITORS | F. HOFMANN-LA ROCHE AG (CH) | 2006-08-03 | — | — | WO | disclosed |
| US-20060167023-A1 | Substituted phenyl methanones | HOFFMANN-LA ROCHE INC. | 2006-07-27 | — | — | US | disclosed |
| US-20050059668-A1 | Substituted acylpiperazine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | US | disclosed |
| WO-2005023261-A1 | 1-BENZOYL-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | WO | disclosed |
| EP-1383760-A1 | BIARYLCARBOXAMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002090347-A1 | AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167023-A1 | Substituted phenyl methanones | SLC6A7, SLC1A1, SLC26A3 | LMNA 2647/4885PTGS2 1679/4885SLC6A9 12/4885 |
| US-20060178381-A1 | Heterocyclic-substituted phenyl methanones | CYP2B6, CYP2D6, CYP1A2 | LMNA 1835/4885PTGS2 1021/4885SLC6A9 1024/4885 |
| US-20050059668-A1 | Substituted acylpiperazine derivatives | AGPAT5, ACHE, GRIK5 | LMNA 4830/4885PTGS2 1773/4885SLC6A9 2325/4885 |
| US-20140357653-A1 | CHEMICAL COMPOUNDS | HCRTR2, HCRTR1, NPY1R | LMNA 3535/4885PTGS2 1736/4885SLC6A9 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.